Directory of Stock Market Company
This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.
Search into NYSE and TSX
by quote, company name or key word
AVEO - Aveo Pharmaceuticals Inc
AVEO Pharmaceuticals, Inc. (AVEO), incorporated on October 19, 2001, is a cancer therapeutics company. The Company focuses on discovering, developing and commercializing targeted cancer therapies to impact patients’ lives. The Company’s product, Tivozanib, is a potent and selective oral inhibitor of the vascular endothelial growth factor (VEGF), receptors 1, 2 an","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"
Aveo Pharmaceuticals Inc News
The top 5 fastest-growing public companies in Mass. (slide show)
Boston Business Journal (blog) - 6 hours ago
Boston Business Journal (blog) - 6 hours ago
No. 5: AMAG Pharmaceuticals Inc. 2011 was a tough year for AMAG (Nasdaq: AMAG). CEO Brian Pereira (pictured) departed, and revenue fell by 7.54 percent, to $61.25 million.
Ariad Pharmaceuticals, ArQule, Exelixis, Aveo, Other Cancer Drug Stocks Fall
Minyanville.com - May 18, 2012
Minyanville.com - May 18, 2012
By Brett Chase May 17, 2012 20:00 pm Stocks for a number of cancer drug developers are falling Thursday as investors sift through scientific papers released ahead of a major medical conference next month.
Share on Facebook
Xconomy - May 18, 2012
Xconomy - May 18, 2012
—Cambridge, MA-based Aveo Pharmaceuticals (NASDAQ: AVEO) and its Japan-based partner Astellas Pharma announced their experimental kidney cancer drug tivozanib reached the main goal in a pivotal of 517 patients.
Biotech-Focused Baker Bros. $3.7B Fund Bought These 3 Big Winners And Sold ...
Seeking Alpha - May 17, 2012
Seeking Alpha - May 17, 2012
New York-based Hedge Fund Baker Bros. Advisors LLC, as of the most recent SEC 13-F Q1 filing, had $3.7 billion in equity assets, almost all invested in the biotech sector, and an increase from the $3.0 billion in Q4 and $2.3 billion in Q3 of 2011.
UPDATED: ASCO abstracts reveal added appeal for key cancer drug prospects
FierceBiotech - May 17, 2012
FierceBiotech - May 17, 2012
The avalanche of ASCO abstracts last night triggered a flurry of news reports about the most notable new data on experimental therapies to be revealed ahead of next month's big meeting in Chicago.
ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)
TheStreet.com - May 17, 2012
TheStreet.com - May 17, 2012
By Adam Feuerstein 05/17/12 - 06:19 AM EDT BOSTON (TheStreet) -- Investors got their first look at thousands of cancer drug research abstracts released Wednesday night by the American Society of Clinical Oncology (ASCO) in advance of its closely ...
ASCO '12 Abstract Dump: Cancer Stocks in Focus
TheStreet.com - May 17, 2012
TheStreet.com - May 17, 2012
By Adam Feuerstein 05/17/12 - 06:19 AM EDT BOSTON (TheStreet) -- Investors got their first look at thousands of cancer drug research abstracts released Wednesday night by the American Society of Clinical Oncology (ASCO) in advance of its closely ...
ASCO 2012: Precision Medicine Applied, Sometimes, Imprecisely
BioWorld Online - May 17, 2012
BioWorld Online - May 17, 2012
The data deluge that is the annual meeting of the American Society of Clinical Oncology (ASCO) began with the release of the abstracts that will be presented at the conference, which will be held June 1-5 this year.
Aveo kidney cancer drug more tolerated than Nexavar
Chicago Tribune - May 16, 2012
AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of ... - EON: Enhanced Online News (press release)
Chicago Tribune - May 16, 2012
(Reuters) - Patients taking a kidney cancer drug being developed by Aveo Pharmaceuticals Inc were half as likely to need a break from the medication due to side effects than those on the widely used medicine Nexavar, according to data released on ...
AVEO PHARMACEUTICALS, INC. : AVEO and Astellas Announce Positive Findings from ... - 4-tradersAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of ... - EON: Enhanced Online News (press release)
BioMed Realty Trust Signs Aveo Pharmaceuticals to 126 KSF Office Lease
Commercial Property Executive - May 11, 2012
Commercial Property Executive - May 11, 2012
By Barbra Murray, Contributing Editor Signs of life are crystal clear in the Cambridge market of metropolitan Boston's life-sciences sector, as evidenced by a sizeable new lease secured by BioMed Realty Trust Inc. Aveo Pharmaceuticals Inc. just inked a ...
Aveo Pharmaceuticals inks deal for new HQ in Kendall Square - Boston Business Journal NYSE Media Coverage Selection of the best articles found in your favorit medias